Cortisporin — Competitive Intelligence Brief

Cortisporin (NEOMYCIN) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Aminoglycoside Antibacterial. Area: Metabolic.

marketed Aminoglycoside Antibacterial Transient receptor potential cation channel subfamily V member 1 Metabolic

Target snapshot

Cortisporin (NEOMYCIN) — Pfizer.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Cortisporin TARGET	NEOMYCIN	Pfizer	marketed	Aminoglycoside Antibacterial	Transient receptor potential cation channel subfamily V member 1	1957-01-01
Qutenza	CAPSAICIN	Averitas	marketed	capsaicin	Transient receptor potential cation channel subfamily V member 1	2009-01-01
Neomycin B	FRAMYCETIN		phase 3	framycetin	Lecithin retinol acyltransferase, Menin, Transient receptor potential cation channel subfamily V member 1
Netromycin	NETILMICIN		marketed	Aminoglycoside Antibacterial		1983-01-01
Arikayce Kit	AMIKACIN	Bristol-Myers Squibb	marketed	Aminoglycoside Antibacterial		1981-01-01
Kanacin	KANAMYCIN	Bristol-Myers Squibb	marketed	Aminoglycoside Antibacterial	Gap junction beta-2 protein	1973-01-01
Garamycin	GENTAMICIN	Merck & Co.	marketed	Aminoglycoside Antibacterial	Transient receptor potential cation channel subfamily V member 5	1970-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Aminoglycoside Antibacterial class)

1. Bristol-Myers Squibb · 2 drugs in this class
2. · 1 drug in this class
3. Merck & Co. · 1 drug in this class
4. Pfizer · 1 drug in this class